{'fraction_non_alphanumeric': 0.030333670374115267, 'fraction_numerical': 0.017189079878665317, 'mean_word_length': 4.561797752808989, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Influence of SEN virus infection on their response to lamivudine in patients with chronic hepatitis B].

OBJECTIVE
To investigate the influence of SEN virus infection on their response to lamivudine in patients with chronic hepatitis B (CHB).


METHODS
SEN virus-D and -H DNA were detected in 45 CHB patients who received lamivudine 12 months with nested-PCR, and YMDD motif mutations in HBV DNA were investigated with gene chip.


RESULTS
The positive rate of SEN virus DNA was 11.1% (5/45), and there were four out of the five SEN virus DNA positive patients whose HBV DNA was positive, among them, two patients existed YMDD motif mutation. While ten out of the forty SEN virus DNA negative patients appeared HBV DNA positive. The response rate was significant lower in SEN virus-infected patients than that in uninfected patients (chi 2=3.97, P<0.05).


CONCLUSION
Coinfection with SEN virus in chronic hepatitis B patients may adversely affect the outcome of treatment with lamivudine